HER2-Positive Uterine Serous Carcinoma: An Equivocal Result and a Fast-Growing Tumor
Trastuzumab's benefit in HER2-positive uterine serous carcinoma was shown in a trial where it started alongside chemotherapy from the first cycle. Her HER2 result came back equivocal, and the confirmatory test that would resolve it takes two weeks — time this particular histology isn't known for giving anyone easily.
Yolanda P., 71, sold the house she had lived in for forty years three months ago and moved into a one-bedroom independent-living apartment across town from her daughter, a decision she made before her diagnosis and has been quietly grateful for since — someone is nearby now, on the days the appointments stack up. Surgical pathology after her hysterectomy returned Stage IIIA uterine serous carcinoma, a histology that accounts for a small share of endometrial cancer overall but a disproportionate share of its deaths, growing and recurring faster than the more common endometrioid subtype even at earlier stages.
HER2 testing on the tumor came back IHC 2+ — equivocal, which means the real HER2 status isn't yet known and won't be until a FISH assay confirms or rules out gene amplification, a test that takes roughly two weeks to result at the reference lab her hospital sends to. That 2+ is not a fixed property of her tumor either: the pivotal trial in this disease read HER2 by modified breast-cancer criteria, an endometrial-serous-specific algorithm has since been proposed and validated against it, and the two do not sort the same tumors into the equivocal band. The trial that established trastuzumab's benefit in this exact disease, a randomized study by Fader and colleagues, enrolled only confirmed HER2-positive patients and started trastuzumab alongside carboplatin-paclitaxel from the very first cycle, showing a real progression-free survival benefit that a later, longer-follow-up analysis extended to overall survival as well. What that trial did not test is what happens when trastuzumab is added a few weeks late, after chemotherapy has already started — which leaves Yolanda's team without a clean answer for whether the two-week FISH delay is a real cost to defer starting chemotherapy over, or a gap in a fast-growing tumor's treatment course that shouldn't be tolerated regardless of what the eventual receptor result turns out to be. Which scoring system a laboratory runs measurably changes how many tumors land in the equivocal band at all, a methodological gap the pathology group has flagged as an open question in its own right — no bearing on how fast today's decision has to be made, but worth naming rather than treating a 2+ score as something the tumor simply is.
Two weeks that neither position wanted to spend
I'd start carboplatin-paclitaxel today and add trastuzumab whenever FISH comes back amplified. Uterine serous carcinoma grows fast enough that we've all watched two-week delays turn into a stage change on the next scan. The cost of starting trastuzumab a cycle late is theoretical. The cost of a two-week treatment delay in this histology specifically is not.
I take the delay risk seriously, but I'd point out the Fader trial's benefit was shown with trastuzumab starting alongside chemotherapy from cycle one — that's the actual tested protocol. Starting them a cycle or two apart is a real modification, and I don't think we know that modification preserves the same benefit, even if it sounds like it should.
"The cost of starting late is theoretical" cuts both ways — we also don't have evidence that it's SAFE to assume the timing doesn't matter. Absence of data isn't itself reassurance in either direction.
I'd push on something neither of you has questioned yet: is two weeks actually the floor for FISH turnaround, or just what the standard workflow defaults to? I'd start chemotherapy today, and in parallel, ask the lab directly whether this specific sample can be expedited. If we can get FISH back in three or four days instead of fourteen, most of this disagreement resolves itself without either of you having to be wrong.
Agreed: carboplatin-paclitaxel started immediately, with the pathology lab agreeing to an expedited FISH turnaround that returned confirmed HER2 amplification on day four — trastuzumab was added starting cycle two, three cycles earlier than the standard testing timeline would have allowed.
Not resolved on principle, only avoided in practice: whether starting trastuzumab asynchronously from chemotherapy actually preserves the pivotal trial's benefit was never answered, because the expedited FISH result meant the team never had to test that assumption on Yolanda specifically.